Clinical Trial Update: Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin mesylate in patients with previously treated metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Carcinoma

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Breast Carcinoma, Stage IV Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-07-23